Yahoo Web Search

  1. An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose ...

  2. Merck & Co., Inc. MRK announced that the FDA has accepted its new drug application (NDA) and a supplemental NDA (sNDA) for its antibacterial medicine Dificid (fidaxomicin) to treat Clostridium ...

  3. NASDAQ: GILD) Type of Application: sNDA Candidate: Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) Indication: Pre-exposure prophylaxis, or PrEP, for HIV-1 infection Date ...

  4. Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene ...

  5. Incyte Treats First Patient in Phase III Vitiligo Study

    Zacks via Yahoo FinanceSep 26 13:02 PM

    Incyte INCY announced that the first patient has been treated in the TRuE-V clinical program evaluating the cream formulation of ruxolitinib as monotherapy for vitiligo. The TRuE-V clinical ...

  6. So shareholders might well want to know whether insiders have been buying or selling shares in Amgen Inc. (NASDAQ:AMGN). It is perfectly legal for company insiders, including board ...

  7. Medicines Company's Inclisiran Succeeds in Pivotal Studies

    Zacks via Yahoo FinanceSep 26 16:05 PM

    The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.

  8. The global cancer biologics market was valued at about $64.06 billion in 2018, and is expected to grow to $87.74 billion at an annual growth rate of 8.2% through 2022. Rising prevalence of chronic ...

  9. Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?

    Zacks via Yahoo FinanceOct 07 13:30 PM

    Amgen (AMGN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question ...

  10. Cutting Rates 50 bps. Smart, Dumb, Not Enough?

    Zacks via Yahoo FinanceSep 26 20:55 PM

    Fed Rate Cut Again: What Does This Mean? Is There A Recession On The Horizon? John Blank's Top Stock Picks Podcast@Zacks.com As was anticipated, the Fed cut the Fed Funds rate a quarter point.

  1. Ads
    related to Amgen Inc